The Radiation Therapy Oncology Group (RTOG) is an instrument of cooperative investigations to increase survival, decrease morbidity, preserve function and quality of life, and increase basic understanding of cancer. Its clinical, laboratory, and biostatistical scientists have made progress against major killers of Americans, especially cancer of the esophagus, lung, cervix, prostate, and anal canal. It has demonstrated equivalent outcomes when treatments are comparable for blacks and whites with brain tumors, and carcinomas of the head and neck, lung and esophagus, and similar results for women and men with malignant gliomas, head and neck and lung cancer. The RTOG plans to continue integration of surgical, radiotherapeutic and chemotherapeutic treatments with emphasis on enhancing local-regional tumor control to improve outcomes. It will continue to investigate 3-dimensional conformal radiation therapy and stereotactic radiosurgery, altered fractionation, and chemical and biologic agents. Phase III trials for brain, head and neck, lung, gastrointestinal and genitourinary tumors are active and new hypotheses will be tested within the RTOG or the integroup mechanism when current studies are completed. A comprehensive quality management program monitors protocol compliance, completeness and accuracy of data, institutional audits and timely reporting of results. The RTOG has an entirely independent data safety and monitoring committee, and its protocols are overseen by an institutional review board with expertise in medical ethics. A Translational Research Program (TRP) chaired by a new Vice-Chair for Basic Science is rapidly advancing correlative studies of clinical, cellular and molecular phenomena; the TRP includes pathologists, tumor biologists and physicians representing all disease sites. A new Vice-Chair for Cancer Control oversees interrelated Community Clinical Oncology Program (CCOP), Special Populations, Epidemiology, Late Effects and Quality of Life investigations. The large databases and long-term observations from RTOG studies serve as unique resources to study major types of cancer. A 19% increase in annual accrual of patients for the last three years compared with the prior four years indicates that the studies of the RTOG investigations will be achieved more rapidly and its results will be available to the practice community and to investigators developing future studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA021661-23S1
Application #
2728854
Study Section
Subcommittee G - Education (NCI)
Project Start
1979-02-01
Project End
2001-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
American College of Radiology
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Ulrich, Connie M; Deshmukh, Snehal; Pugh, Stephanie L et al. (2018) Attrition in NRG Oncology's Radiation-Based Clinical Trials. Int J Radiat Oncol Biol Phys 102:26-33
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Lawrence, Yaacov R; Moughan, Jennifer; Magliocco, Anthony M et al. (2018) Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer 124:491-498
Rogers, Leland; Zhang, Peixin; Vogelbaum, Michael A et al. (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129:35-47
Raman, Srinivas; Ding, Keyue; Chow, Edward et al. (2018) Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. Qual Life Res 27:1089-1098
Lieberman, Frank S; Wang, Meihua; Robins, H Ian et al. (2018) Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. Int J Radiat Oncol Biol Phys :
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Seider, Michael J; Pugh, Stephanie L; Langer, Corey et al. (2018) Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 32:553-560
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Regine, William F; Winter, Kathryn; Abrams, Ross A et al. (2018) Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 3:154-162

Showing the most recent 10 out of 591 publications